TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, Jan. 4, 2023 /CNW/ - TSX VENTURE COMPANIES ELEVATION GOLD MINING CORPORATION ("ELVT.WT") BULLETIN TYPE: Warrant Expiry-Delist BULLETIN DATE: January 4, 2023 TSX Venture Tier 2 Co...
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise. RepliCel Life Sciences Inc. is based in Vancouver, Canada.
0.043 | |
0.043 | |
- | |
0.043 | |
0.043 | |
0.026-0.095 | |
2 795 K | |
65 002 K | |
354 K | |
-0.0022 | |
0.828 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
VANCOUVER, BC, Jan. 4, 2023 /CNW/ - TSX VENTURE COMPANIES ELEVATION GOLD MINING CORPORATION ("ELVT.WT") BULLETIN TYPE: Warrant Expiry-Delist BULLETIN DATE: January 4, 2023 TSX Venture Tier 2 Co...
MainPointe Deal Positions RepliCel for entry into the U.S. market and significant milestones in Japan VANCOUVER, BC / ACCESSWIRE / January 25, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: